182 related articles for article (PubMed ID: 21054332)
1. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts.
Sánchez-Moya AI; Daudén E
Br J Dermatol; 2011 Jan; 164(1):208-9. PubMed ID: 21054332
[No Abstract] [Full Text] [Related]
2. [The relevance of diagnostic criteria for latent tuberculosis before initiation of TNF-alpha inhibitors in psoriasis patients].
Goujon C; Gormand F; Gunera-Saad N; Dahel K; Vial T; Nicolas JF
Ann Dermatol Venereol; 2010; 137(6-7):437-43. PubMed ID: 20620572
[TBL] [Abstract][Full Text] [Related]
3. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test.
Laffitte E; Janssens JP; Roux-Lombard P; Thielen AM; Barde C; Marazza G; Panizzon RG; Saurat JH
Br J Dermatol; 2009 Oct; 161(4):797-800. PubMed ID: 19659473
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
5. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
[TBL] [Abstract][Full Text] [Related]
6. Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report.
Skroza N; Proietti I; Bernardini N; La Viola G; Nicolucci F; Tolino E; Zuber S; Potenza C
Cutis; 2012 Sep; 90(3):120-2. PubMed ID: 23094309
[TBL] [Abstract][Full Text] [Related]
7. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
Downs AM
Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
[No Abstract] [Full Text] [Related]
8. Tumor necrosis factor-alpha blocker induced tuberculosis.
Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
[No Abstract] [Full Text] [Related]
9. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
[No Abstract] [Full Text] [Related]
10. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
11. Secondary leprosy infection in a patient with psoriasis during treatment with infliximab.
Teixeira FM; Vasconcelos LM; Rola Cde A; Prata de Almeida TL; Valença JT; Nagao-Dias AT
J Clin Rheumatol; 2011 Aug; 17(5):269-71. PubMed ID: 21778902
[TBL] [Abstract][Full Text] [Related]
12. Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis.
Huo R; Romanelli P
Am J Clin Dermatol; 2010; 11 Suppl 1():39-40. PubMed ID: 20586506
[TBL] [Abstract][Full Text] [Related]
13. Consecutive use of different biological therapies in the treatment of psoriasis.
Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
[No Abstract] [Full Text] [Related]
14. Double screening for latent tuberculosis infection in patients treated with anti-tumor necrosis factor α.
Sempau L; González-Sixto B; Sánchez-Sambucetty P; de Morales JM; Pérez-Bustillo A; Rodríguez-Prieto MA
Arch Dermatol; 2011 Oct; 147(10):1233-4. PubMed ID: 22006153
[No Abstract] [Full Text] [Related]
15. Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: a combined approach by QuantiFERON-TB Gold and tuberculin skin tests.
Prignano F; Bartoloni A; Bartalesi F; Gori A; Ricceri F; Cavallo A; Attala L; Mantella A
Int J Dermatol; 2014 Aug; 53(8):e372-4. PubMed ID: 24898978
[No Abstract] [Full Text] [Related]
16. Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-α antagonists: implications for management?
Teh BW; Street AC; McBryde ES; Denholm JT
J Rheumatol; 2012 Jun; 39(6):1297-8. PubMed ID: 22661422
[No Abstract] [Full Text] [Related]
17. [Up-date on the use of infliximab in dermatology. Introduction].
Sánchez-Carazo J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
[No Abstract] [Full Text] [Related]
18. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
Takahashi MD; Castro LG; Romiti R
Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
[No Abstract] [Full Text] [Related]
19. New development in the treatment of psoriasis--infliximab.
Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008
[TBL] [Abstract][Full Text] [Related]
20. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
